Pt계 촉매를 이용한 직접 개미산 연료전지의 특성 연구

유재근,이효송,김진용,김기호,이영우 충남대학교 공업교육연구소 2005 論文集 Vol.27 No.1

Direct Formic Acid Fuel Cells (DFAFCs) are potential alternative power sources for potable devices such as cellular phones, personal digital assistants (PDA) and laptop computers. In this study, we investigated the effect of the anode catalysts on the performance of direct formic acid fuel cell. We made the Pt-Pd catalysts using deposition method for the investigation of the fuel cell performance as a change of temperature and oxidant. Fuel cell with Pt-Pd anode catalyst showed the performance of 120 mW/㎠at room temperature. This result was much higher value than that of Pt-Ru catalyst which showed the best performance of commercial catalyst in our previous works. For this reason, we can conclude that the Pt-Pd catalyst is an excellent material for the oxidation of formic acid.

파종시기가 다른 일미찰의 등숙 중 호화 특성 비교

김미정, 박효진, 이유영, 김선림, 김정태, 우관식, 권영업, 정일민 忠北大學校 農業科學硏究所 2014 農業科學硏究 Vol.30 No.2

This study was conducted to investigate the pasting properties of waxy corn ‘Ilmichal’ during ripening with different sowing date. Starch content of Ilmichal was increased as matured (p<0.05). Analysis of pasting properties with waxy corn starch using a rapid visco analyser (RVA) showed linear changes in peak viscosity, trough viscosity, final viscosity, breakdown and consistency according to ripening. There were significantly positive correlation between starch content of Ilmichal and peak viscosity (0.39*), trough viscosity (0.58***), final viscosity (0.58***), and consistency (0.57**). Differential scanning calorimerty (DSC). The enthalpy of gelatinization was increased as ripening. But onset and peak temperature were decreased. There were significantly positive correlation between starch content of Ilmichal and onset temperature (0.44*), peak temperature (0.38*), and completion temperature (0.59***), on the other hand, crude protein content presented significantly negative correlation between completion temperature (-0.41*).

나노입자의 크기효과와 체적분율 효과를 동시 고려한 나노복합재의 멀티스케일 브리징 해석기법에 관한 연구

양승화,유수영,조맹효,Yang, Seung-Hwa,Yu, Su-Young,Cho, Maeng-Hyo 한국전산구조공학회 2009 한국전산구조공학회논문집 Vol.22 No.4

본 연구에서는 분자동역학 전산모사와 미시역학 모델을 이용하여 나노입자의 체적분율이 높은 경우 나노 입자의 크기효과와 체적분율 효과가 나노복합재의 기계적 물성에 미치는 영향을 효과적으로 묘사할 수 있는 순차적 브리징 해석기법을 제안하였다. 체적분율이 12%로 고정된 상태에서 나노입자의 크기변화에 따른 영률과 전단계수를 분자동역학 전산모사를 통해 예측한 후, 이를 연속체 모델에서 구현하기 위해 다중입자모델을 적용하였다. 나노입자의 크기효과를 반영하기 위해 입자와 기지 사이에 유효계면을 추가적인 상으로 도입하였고, 12%의 체적분율 조건에서 나타날 수 있는 체적분율 효과는 나노복합재를 둘러싸는 가상의 영역인 무한영역의 물성값의 변화를 통해 조절되도록 하였다. 유효계면과 무한영역의 물성을 입자의 반경에 대한 함수로 근사한 후 다양한 입자의 크기에서 나타나는 나노복합재의 물성변화의 예측이 가능하도록 하였다. 제안된 브리징 해석기법의 적용을 통해 분자동역학 해석결과와 잘 일치하는 결과를 연속체 모델에서 효율적이고 정확하게 얻을 수 있었다. 또한 유효계면의 두께와 물성 변화가 나노복합재의 기계적 물성에 미치는 영향을 고찰하였다. In this study, an efficient sequential bridging method to characterize both the particle size effect and concentration effect on the mechanical properties of nanocomposites at high volume fraction is suggested through a molecular dynamics(MD) simulations and micromechanics of composites materials. The Young's modulus and the shear modulus of the nanocomposites at various particle radius and at 12% volume fraction were obtained from MD simulations and multi-inclusion model was adopted to describe both modulus in continuum model. In order to describe the particle size effect, an additional phase, effective interface, was adopted as characteristic phase and the non-dilute concentration effect which appears at 12% volume fraction was describe via the variation of the elastic modulus of the infinite medium. Both the elastic modulus of the interface and infinite medium were fitted into functions of particle radius for the applicability of the present bridging method at various particle radii. Using the present bridging method the elastic modulus of the nanocomposites was efficiently obtained with accuracy. In addition, the effect of the interface thickness and modulus on the elastic modulus of the nanocomposite was investigated.

Ranitidine, Sucralfate, Bismuth Subcitrate 복합제의 흰쥐 위궤양에 대한 치료효과

조태순,조광재,주일로,이선미,유영효 成均館大學校 科學技術硏究所 1994 論文集 Vol.45 No.1

Gastric ulcer disease results when there is an imbalance between aggressive factors(acid secretion) and protective factors(mucosal defence). H_2-receptor antagonists are the most frequently used agents for treatment of gastric ulcer disease. However, use of these products should be determined by potential for adverse effects, drug interactions and cost. Ranitidine, H_2 - receptor antagonist, competitively block the H_Z-receptor on the parietal cell, causing inhibition of gastric acid secretion. Sucralfate and bismuth subcitrate coat ulcer craters and then enhance mucosal defence. Bismuth subcitrate also causes detachment of Helicobacter pylori from the gastric epithelium with subsequent lysis of the bacteria. To estimate effects of the mixture of ranitidine 20mg/kg, bismuth subcitrate 40mg/kg and sucralfate 120mg/kg on aspirin - HCl induced gastric ulcer in rats, gastric ulceration, pH, gastric secretion, free and total acidity, pepsin activity, gastric mucosal hemorrhage were investigated. Results obtained were as follow : 1) The mixture showed remarkable suppression of gastric ulceration, pH, gastric secretion, free and total acidity, pepsin activity, gastric mucosal hemorrhage compared with ranitidine alone. 2) With elapse of time, the mixture showed more increasing inhibitory effects on gastric ulceration, pH, gastric secretion, pepsin activity, gastric mucosal hemorrhage than sucralfate and bismuth subcitrate.

Original Article : Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma

( Hyo Jeong Lee ),( Hyo Jeong Kang ),( Kang Mo Kim ),( Eun Sil Yu ),( Ki Hun Kim ),( Seung Mi Kim ),( Tae Won Kim ),( Ju Hyun Shim ),( Young Suk Lim ),( Han Chu Lee ),( Young Hwa Chung ),( Yung Sang L 대한간학회 2015 Clinical and Molecular Hepatology(대한간학회지) Vol.21 No.1

Background/Aims: Fibroblast growth factor signaling is involved in hepatocarcinogenesis. The aim of this study was to determine the fibroblast growth factor receptor (FGFR) isotype expression in hepatocellular carcinoma (HCC) and neighboring nonneoplastic liver tissue, and elucidate its prognostic implications. Methods: Immunohistochemical staining of FGFR1, -2, -3, and -4 was performed in the HCCs and paired neighboring nonneoplastic liver tissue of 870 HCC patients who underwent hepatic resection. Of these, clinical data for 153 patients who underwent curative resection as a primary therapy were reviewed, and the relationship between FGFR isotype expression and overall survival was evaluated (development set). This association was also validated in 73 independent samples (validation set) by Western blot analysis. Results: FGFR1, -2, -3, and -4 were expressed in 5.3%, 11.1%, 3.8%, and 52.7% of HCCs, respectively. Among the development set of 153 patients, FGFR2 positivity in HCC was associated with a significantly shorter overall survival (5-year survival rate, 35.3% vs. 61.8%; P=0.02). FGFR2 expression in HCC was an independent predictor of a poor postsurgical prognosis (hazard ratio, 2.10; P=0.02) in the development set. However, the corresponding findings were not statistically significant in the validation set. Conclusions: FGFR2 expression in HCC could be a prognostic indicator of postsurgical survival. (Clin Mol Hepatol 2015;21:60-70)

The genome-wide expression profile of 1,2,3,4,6-penta-O-galloyl-β-D-glucose-treated MDA-MB-231 breast cancer cells: Molecular target on cancer metabolism

Yu, Woo Sik,Jeong, Soo-Jin,Kim, Ji-Hyun,Lee, Hyo-Jung,Song, Hyo Sook,Kim, Min-Seok,Ko, Eunjung,Lee, Hyo-Jeong,Khil, Jae-Ho,Jang, Hyeung-Jin,Kim, Young Chul,Bae, Hyunsu,Chen, Chang Yan,Kim, Sung-Hoon Springer-Verlag 2011 Molecules and cells Vol.32 No.2

Adjuvant Cytokine-Induced Killer Cell Immunotherapy for Hepatocellular Carcinoma: A Real-World Experience

( Hyo Young Lee ),( Jeong-hoon Lee ),( Joon Yeul Nam ),( Young Chang ),( Hyeki Cho ),( Young Youn Cho ),( Eun Ju Cho ),( Su Jong Yu ),( Yoon Jun Kim ),( Jung-hwan Yoon ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1

Aims: Recent clinical studies showed that immunotherapy with cytokine induced killer (CIK) cell are an effective adjuvant treatment for hepatocellular carcinoma (HCC) after potentially curative treatment. The aim of this study was to investigate the efficacy of CIK cell immunotherapy in real-world clinical practice. Methods: The study included 36 consecutive patients who were treated with CIK cells at a single institution. The primary endpoint was recurrence-free survival (RFS). Cox proportional hazard model was utilized to evaluate independent prognostic factors. Results: At baseline, 27 patients (75%) patients had stage I or II HCC and 9 (25%) had stage III HCC. Mean size of largest tumor was 3.2±2.3cm. Eighteen patients (50%) underwent surgical resection, 9 radiofrequency ablation, 1 percutaneous ethanol injection, and 5 transarterial chemoembolization. Three patients underwent living do nor liver transplantation (LDLT) for far beyond Milan criteria HCC. During a study period (median, 11.5 months), 11 patients experienced tumor recurrence and there was no death. The median RFS was 15 months. In multivariable analysis, stage III was independently associated with higher risk of tumor recurrence (vs stage I: hazard ratio, 5.09; 95% confidence interval, 1.19-21.78; P=0.03). Notably, among three patients who underwent LDLT for far-advanced HCC, one did not show recurrence till 8 months. Conclusions: This study shows that advanced tumor stage remains an independent risk factor of early recurrence. It is warranted to evaluate the effect of CIK cell immunotherapy in patients with advanced stage HCC.

Clinical Practice Guidelines for Managing Frailty in Community-Dwelling Korean Elderly Adults in Primary Care Settings

Hyo-Sun You,Yu-Jin Kwon,Sun Young Kim,Yang Hyun Kim,Ye-Seul Kim,Yonghwan Kim,노용균,Byoungjin Park,Young-Kyu Park,Chang-Hae Park,Joung Sik Son,Jinyoung Shin,Hyun-Young Shin,Bumjo Oh,이재우,Jae-YongShim,Chan 대한가정의학회 2021 Korean Journal of Family Medicine Vol.42 No.6

Aging has become a global problem, and the interest in healthy aging is growing. Healthy aging involves a focus on the maintenance of the function and well-being of elderly adults, rather than a specific disease. Thus, the management of frailty, which is an accumulated decline in function, is important for healthy aging. The adaptation method was used to develop clinical practice guidelines on frailty management that are applicable in primary care settings. The guidelines were developed in three phases: preparation (organization of committees and establishment of the scope of develop-ment), literature screening and evaluation (selection of the clinical practice guidelines to be adapted and evaluation of the guidelines using the Korean Appraisal of Guidelines for Research and Evaluation II tool), and confirmation of recom-mendations (three rounds of Delphi consensus and internal and external reviews). A total of 16 recommendations (five recommendations for diagnosis and assessment, 11 recommendations for intervention of frailty) were made through the guideline development process. These clinical practice guidelines provide overall guidance on the identification, evalua-tion, intervention, and monitoring of frailty, making them applicable in primary care settings. As aging and “healthy ag-ing” become more and more important, these guidelines are also expected to increase in clinical usefulness.

Basic, HCC basic : O-036 ; Fibroblast growth factor isotype expression pattern and its association with overall survival in patients with hepatocellular carcinoma

( Hyo Jeong Lee ),( Hyo Jeong Kang ),( Eun Sil Yu ),( Kang Mo Kim ),( Ju Hyun Shim ),( Young Suk Lim ),( Han Chu Lee ),( Young Hwa Chung ),( Yung Sang Lee ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1

Background: Fibroblast growth factor receptor (FGFR) have been reported to be involved in the progression of hepatocellular carcinoma (HCC). There are 4 isotypes of FGFR (FGFR1-4) and the expression pattern of each FGFR isotype in HCC is still unknown. This study is aimed to assess FGFR isotype expression pattern in HCC and neighbouring non-neoplastic liver tissue and to evaluate the relationship between FGFR isotype expression pattern and overall survival (OS) of patients. Methods: We performed immunohistochemical staining of FGFR1, 2, 3 and 4 in HCC and paired neighboring nonneoplastic liver tissues of 870 HCC patients who underwent hepatic resection from 1998 to 2004. Among these patients, clinical data of 153 patients, who received curative resection as primary therapy from 2003 to 2004, was reviewed retrospectively and association of FGFR isotype expression with clinical parameter was also evaluated. Results: Among total 870 patients, expression of FGFR1, 2, 3 and 4 were observed in 5.3, 18.7, 3.8 and 52.9% of HCC tissues, respectively. FGFR1 and 4 were positive in 5.9 and 82.9% of non-neoplastic liver tissues but FGFR2 and 3 were not expressed in adjacent liver tissue. Among 153 patients whose clinical parameters were reviewed, the patients with positive FGFR2 staining in HCC tissue showed significantly shorter OS than the patients with negative FGFR2 (5-year survival rate 35.3 vs 61.8%, p=0.02). However, there was no significant difference in OS of patients according to the expression of FGFR1, 3 and 4 in HCC tissues. In multivariate analysis of potential factors to affect OS, FGFR2 expression in HCC tissue was an independent predictor of poor prognosis in postsurgical survival of HCC patients(hazard ratio 2.10, p=0.02). Conclusions: FGFR2 expression in HCC tissue might be used as a valuable prognostic biomarker for HCC patients after hepatic resection and also be a novel therapeutic target for molecular targeted agent in HCC.

Comparison of End of Treatment Response and Sustained Virologic Response in Direct-Acting Antiviral Agents-Treated Chronic Hepatitis C Patients

( Young Chang ),( Jeong-hoon Lee ),( Joon Yeul Nam ),( Hyo Young Lee ),( Hyeki Cho ),( Young Youn Cho ),( Eun Ju Cho ),( Su Jong Yu ),( Yoon Jun Kim ),( Jung-hwan Yoon ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1

Aims: The concordance among end of treatment response (ETR) and sustained virologic response at week 12 (SVR12) and 24 (SVR24) has not been well evaluated in patients treated with interferon-free direct acting antiviral agents (DAA). We aimed to assess the correlation between ETR, SVR12, and SVR24. Methods: We conducted a single-center retrospective study including DAA-treated patients with chronic hepatitis C whose virologic response was evaluated after the end of treatment. Viral load was estimated with real-time quantitative RT-PCR (lower limit of detection, 12 IU/mL). Results: This study included 282 patients whose SVR12 was evaluated among 417 patients who finished DAA treatment as scheduled. ETR could accurately predicted SVR12 in 270 of the 282 patients (95.7%), making sensitivity of 98.5% (95% confidence interval, 96.2-99.6%), specificity of 38.5% (95% CI, 13.9-68.4%), positive predictive value (PPV) of 97.1% (95% CI, 95.6-98.1%), and negative predictive value of 55.6% (95% CI, 27.5-80.4%). Interestingly, 44.4% of patients without ETR (4 of 9) achieved SVR12. In contrast, 2.9% of patients with ETR (8 of 273) did not achieved SVR12. The results of SVR12 and SVR24 were identical in 98.7% of evaluated patients (75 of 76 patients). SVR12 could predict SVR12 with sensitivity of 100% (95% CI, 94.6-100.0%), specificity of 88.9% (95% CI, 51.8-99.7%), PPV of 98.5% (95% CI, 91.4-99.8%), and NPV of 100% (95% CI, 100-100%). Conclusions: ETR can accurately predict SVR12, which is also closely correlated with SVR24. Surprisingly, SVR12 was achieved in 44% of the patients who failed to achieve ETR, which might suggest delayed effect of DAA on HCV clearance.